Announces a partnership with TheraPsil - a non-profit coalition made up of healthcare professionals, patients, community members, and advocates dedicated to helping Canadians in medical need access legal psilocybin-assisted psychotherapy and GMP-quality psilocybin. Under the Partnership, TheraPsil will support prescribing healthcare professionals in requesting psilocybin from HAVN Life, and other licensed dealers enrolled in TheraPsil's "Project Solace", through the Special Access Program. Health Canada has designated the Special Access Program, along with clinical trials, as a preferred pathway for patients to access psilocybin for medical purposes. HAVN Life Sciences shares C.HAVN are trading -8.33% at $0.05.
Stocks in play: HAVN Life Sciences
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)